Italian Medicines Agency

01/26/2024 | News release | Distributed by Public on 01/26/2024 08:49

EMA conferma le misure per ridurre al minimo il rischio di effetti collaterali gravi con i prodotti medicinali contenenti pseudoefedrina Notizia in evidenza

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.